Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7935)
All Articles published online
|
Jul 28, 2011 (publication date) through Nov 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wang BJ, Bao JJ, Wang JZ, Wang Y, Jiang M, Xing MY, Zhang WG, Qi JY, Roggendorf M, Lu MJ, Yang DL. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol 2011; 17(28): 3322-3329 [PMID: 21876620 DOI: 10.3748/wjg.v17.i28.3322] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v17/i28/3322.htm |
| Number | Citing Articles |
| 1 |
Kristian Aarslev, Anders Dige, Stinne R. Greisen, Martin Kreutzfeldt, Niels Jessen, Hendrik Vilstrup, Bent Deleuran, Henning Grønbæk. Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis. Scandinavian Journal of Gastroenterology 2017; 52(1): 93 doi: 10.1080/00365521.2016.1233576
|
| 2 |
Glauco Akelinghton Freire Vitiello, Wallax Augusto Silva Ferreira, Vladmir Cláudio Cordeiro de Lima, Tiago da Silva Medina. Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.782852
|
| 3 |
Vishakha Singh, Amit Khurana, Prince Allawadhi, Anil Kumar Banothu, Kala Kumar Bharani, Ralf Weiskirchen. Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.790963
|
| 4 |
Mercedes Iñarrairaegui, Delia D’Avola, Bruno Sangro. Immunotherapy of Hepatocellular Carcinoma. 2017; : 51 doi: 10.1007/978-3-319-64958-0_4
|
| 5 |
Liyuan Hao, Shenghao Li, Jiali Deng, Na Li, Fei Yu, Zhi Jiang, Junli Zhang, Xinli Shi, Xiaoyu Hu. The current status and future of PD-L1 in liver cancer. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1323581
|
| 6 |
Min Deng, Shao-Hua Li, Xu Fu, Xiao-Peng Yan, Jun Chen, Yu-Dong Qiu, Rong-Ping Guo. Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients. Cancer Cell International 2021; 21(1) doi: 10.1186/s12935-021-02081-w
|
| 7 |
Christopher E Jensen, Arturo Loaiza-Bonilla, Paula A Bonilla-Reyes. Immune checkpoint inhibitors for hepatocellular carcinoma. Hepatic Oncology 2016; 3(3): 201 doi: 10.2217/hep-2016-0004
|
| 8 |
Sophia Heinrich, Darko Castven, Peter R. Galle, Jens U. Marquardt. Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. Cancers 2020; 12(9): 2495 doi: 10.3390/cancers12092495
|
| 9 |
Meng Gao, Yonghua Guo, Jinghua Li, Xi Chen, Yufeng Yuan, Weijie Ma. The Clinicopathological Significance and Prognostic Value of PD-L2 in Patients with HCC, ICC and PAAD: A Meta-Analysis. International Journal of Surgery Oncology 2022; 7(1): 81 doi: 10.29337/ijsonco.142
|
| 10 |
Mariko Ishibashi, Hiromi Yamaguchi, Yukari Hirotani, Akihisa Sakurada, Toshihide Endo, Masahiko Sugitani, Tadatoshi Takayama, Makoto Makishima, Mariko Esumi. Contradictory intrahepatic immune responses activated in high-load hepatitis C virus livers compared with low-load livers. Archives of Virology 2018; 163(4): 855 doi: 10.1007/s00705-017-3675-8
|
| 11 |
Claudia A. M. Fulgenzi, Thomas Talbot, Sam M. Murray, Marianna Silletta, Bruno Vincenzi, Alessio Cortellini, David J. Pinato. Immunotherapy in Hepatocellular Carcinoma. Current Treatment Options in Oncology 2021; 22(10) doi: 10.1007/s11864-021-00886-5
|
| 12 |
Cheng-Piao Luo, Han-Yue Mo, Ling-Ling Wu, Yun Ma, Ning-Fu Peng. Soluble PD-L1 and prognosis of patients with hepatocellular carcinoma. European Journal of Cancer 2017; 71: 117 doi: 10.1016/j.ejca.2016.09.040
|
| 13 |
Maridi Aerts, Daphné Benteyn, Hans Van Vlierberghe, Kris Thielemans, Hendrik Reynaert. Current status and perspectives of immune-based therapies for hepatocellular carcinoma. World Journal of Gastroenterology 2016; 22(1): 253-261 doi: 10.3748/wjg.v22.i1.253
|
| 14 |
Scott Balsitis, Volodymyr Gali, Pamela J. Mason, Susan Chaniewski, Steven M. Levine, Michael J. Wichroski, Michael Feulner, Yunling Song, Karen Granaldi, James K. Loy, Chris M. Thompson, Jacob A. Lesniak, Catherine Brockus, Narendra Kishnani, Stephan Menne, Mark I. Cockett, Renuka Iyer, Stephen W. Mason, Daniel J. Tenney, Isabelle Chemin. Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection. PLOS ONE 2018; 13(2): e0190058 doi: 10.1371/journal.pone.0190058
|
| 15 |
Daniel M. Girardi, Jana Priscila M. Pacífico, Fernanda P. L. Guedes de Amorim, Gustavo dos Santos Fernandes, Marcela C. Teixeira, Allan A. L. Pereira. Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives. Pharmaceuticals 2020; 14(1): 28 doi: 10.3390/ph14010028
|
| 16 |
Amisha Singh, Ryan J. Beechinor, Jasmine C. Huynh, Daneng Li, Farshid Dayyani, Jennifer B. Valerin, Andrew Hendifar, Jun Gong, May Cho. Immunotherapy Updates in Advanced Hepatocellular Carcinoma. Cancers 2021; 13(9): 2164 doi: 10.3390/cancers13092164
|
| 17 |
Edoardo Giannini, Andrea Aglitti, Mauro Borzio, Martina Gambato, Maria Guarino, Massimo Iavarone, Quirino Lai, Giovanni Levi Sandri, Fabio Melandro, Filomena Morisco, Francesca Ponziani, Maria Rendina, Francesco Russo, Rodolfo Sacco, Mauro Viganò, Alessandro Vitale, Franco Trevisani. Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. Cancers 2019; 11(11): 1689 doi: 10.3390/cancers11111689
|
| 18 |
Omneya Y. Bassyoni, Heba M. Rashad. Expression of PD-1/PD-L1 and P53 in hepatocellular carcinoma. Egyptian Journal of Pathology 2018; 38(1): 131 doi: 10.1097/01.XEJ.0000542236.83764.02
|
| 19 |
Zuzana Macek Jilkova, Caroline Aspord, Keerthi Kurma, Anouck Granon, Christian Sengel, Nathalie Sturm, Patrice N. Marche, Thomas Decaens. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. Clinical and Translational Gastroenterology 2019; 10(7): e00058 doi: 10.14309/ctg.0000000000000058
|
| 20 |
Michela Guardascione, Giuseppe Toffoli. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma. International Journal of Molecular Sciences 2020; 21(17): 6302 doi: 10.3390/ijms21176302
|
| 21 |
Samantha M. Ruff, Timothy M. Pawlik. Emerging data on immune checkpoint inhibitors in the neoadjuvant and adjuvant setting for patients with hepatocellular carcinoma. Hepatoma Research 2024; doi: 10.20517/2394-5079.2023.144
|
| 22 |
|
| 23 |
Zhu Li, Na Li, Fang Li, Zhihua Zhou, Jiao Sang, Yanping Chen, Qunying Han, Yi Lv, Zhengwen Liu. Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma. Medicine 2016; 95(52): e5749 doi: 10.1097/MD.0000000000005749
|
| 24 |
Hazel Lote, Catherine Cafferkey, Ian Chau. PD-1 and PD-L1 blockade in gastrointestinal malignancies. Cancer Treatment Reviews 2015; 41(10): 893 doi: 10.1016/j.ctrv.2015.09.004
|
| 25 |
Junsik Park, Minsuk Kwon, Eui-Cheol Shin. Immune checkpoint inhibitors for cancer treatment. Archives of Pharmacal Research 2016; 39(11): 1577 doi: 10.1007/s12272-016-0850-5
|
| 26 |
Hyung‑Wook Chun, Ran Hong. Significance of PD‑L1 clones and C‑MET expression in hepatocellular carcinoma. Oncology Letters 2019; doi: 10.3892/ol.2019.10222
|
| 27 |
Zuzana Macek Jilkova, Caroline Aspord, Thomas Decaens. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. Cancers 2019; 11(10): 1554 doi: 10.3390/cancers11101554
|
| 28 |
G. Lin, W. Zhuang, X.H. Chen, C. Huang, X.D. Lin, Y.J. Huang, C. Li. Increase of programmed death ligand 1 in non-small-cell lung cancers with chronic hepatitis B. Annals of Oncology 2018; 29(2): 516 doi: 10.1093/annonc/mdx694
|
| 29 |
Valeria Barili, Carolina Boni, Marzia Rossi, Andrea Vecchi, Alessandra Zecca, Amalia Penna, Gabriele Missale, Carlo Ferrari, Paola Fisicaro. Metabolic regulation of the HBV-specific T cell function. Antiviral Research 2021; 185: 104989 doi: 10.1016/j.antiviral.2020.104989
|
| 30 |
Yukinori Endo, Katie L. Winarski, Md Sanaullah Sajib, Anna Ju, Wen Jin Wu. Atezolizumab Induces Necroptosis and Contributes to Hepatotoxicity of Human Hepatocytes. International Journal of Molecular Sciences 2023; 24(14): 11694 doi: 10.3390/ijms241411694
|
| 31 |
Xuejing Sun, Junru Wu, Lun Liu, Yuanyuan Chen, Yan Tang, Suzhen Liu, Hang Chen, Youxiang Jiang, Yuanyuan Liu, Hong Yuan, Yao Lu, Zhaoyang Chen, Jingjing Cai. Transcriptional switch of hepatocytes initiates macrophage recruitment and T-cell suppression in endotoxemia. Journal of Hepatology 2022; 77(2): 436 doi: 10.1016/j.jhep.2022.02.028
|
| 32 |
Chien-Yu Lin, Evanthia Omoscharka, Yanli Liu, Kun Cheng. Establishment of a Rat Model of Alcoholic Liver Fibrosis with Simulated Human Drinking Patterns and Low-Dose Chemical Stimulation. Biomolecules 2023; 13(9): 1293 doi: 10.3390/biom13091293
|
| 33 |
Samantha M. Ruff, Ashish Manne, Jordan M. Cloyd, Mary Dillhoff, Aslam Ejaz, Timothy M. Pawlik. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Current Oncology 2023; 30(6): 5863 doi: 10.3390/curroncol30060439
|
| 34 |
Nguyen Hai Nam, Kojiro Taura, Yukinori Koyama, Takahiro Nishio, Gen Yamamoto, Yusuke Uemoto, Yusuke Kimura, Li Xuefeng, Daichi Nakamura, Kenji Yoshino, Eri Ogawa, Tatsuya Okamoto, Atsushi Yoshizawa, Satoru Seo, Keiko Iwaisako, Tomoaki Yoh, Koichiro Hata, Toshihiko Masui, Hideaki Okajima, Hironori Haga, Shinji Uemoto, Etsuro Hatano. Increased Expressions of Programmed Death Ligand 1 and Galectin 9 in Transplant Recipients Who Achieved Tolerance After Immunosuppression Withdrawal. Liver Transplantation 2022; 28(4): 647 doi: 10.1002/lt.26336
|
| 35 |
Nobuhiro Tsuchiya, Yu Sawada, Itaru Endo, Yasushi Uemura, Tetsuya Nakatsura. Potentiality of immunotherapy against hepatocellular carcinoma. World Journal of Gastroenterology 2015; 21(36): 10314-10326 doi: 10.3748/wjg.v21.i36.10314
|
| 36 |
Shengkui Tan, Xuefeng Guo, Chunhua Bei, Huixia Zhang, Di Li, Xiaonian Zhu, Hongzhuan Tan. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma. BMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-09999-y
|
| 37 |
Sean P. Martin, Neil Mehta, Juliet Emamaullee. Immune checkpoint inhibitors in liver transplantation: Current practice, challenges, and opportunities. Liver Transplantation 2024; 30(7): 742 doi: 10.1097/LVT.0000000000000350
|
| 38 |
Ken Takahashi, Hiroyuki Marusawa. Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy. Current Human Cell Research and Applications 2018; : 93 doi: 10.1007/978-981-10-6469-2_6
|
| 39 |
Coskun Ozer Demirtas, Feyza Gunduz. Programmed Cell Death 1 and Hepatocellular Carcinoma: An Epochal Story. Journal of Gastrointestinal Cancer 2021; 52(4): 1217 doi: 10.1007/s12029-021-00758-z
|
| 40 |
Jin Yun, Genhua Yu, Pingping Hu, Yang Chao, Xingyu Li, Xiaobo Chen, Qichun Wei, Junfeng Wang. PD-1 expression is elevated in monocytes from hepatocellular carcinoma patients and contributes to CD8 T cell suppression. Immunologic Research 2020; 68(6): 436 doi: 10.1007/s12026-020-09155-3
|
| 41 |
Chiao-Fang Teng, Tsai-Chung Li, Ting Wang, Tzu-Hua Wu, John Wang, Han-Chieh Wu, Woei-Cherng Shyu, Ih-Jen Su, Long-Bin Jeng. <p>Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant</p>. Journal of Hepatocellular Carcinoma 2020; : 385 doi: 10.2147/JHC.S282818
|
| 42 |
Wenfeng Fang, Shaodong Hong, Nan Chen, Xiaobo He, Jianhua Zhan, Tao Qin, Ting Zhou, Zhihuang Hu, Yuxiang Ma, Yuanyuan Zhao, Ying Tian, Yunpeng Yang, Cong Xue, Yanna Tang, Yan Huang, Hongyun Zhao, Li Zhang. PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival. Oncotarget 2015; 6(32): 33019 doi: 10.18632/oncotarget.5028
|
| 43 |
James J. Harding, Imane El Dika, Ghassan K. Abou‐Alfa. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?. Cancer 2016; 122(3): 367 doi: 10.1002/cncr.29769
|
| 44 |
Smitha Menon, Sarah Shin, Grace Dy. Advances in Cancer Immunotherapy in Solid Tumors. Cancers 2016; 8(12): 106 doi: 10.3390/cancers8120106
|
| 45 |
Junyu Long, Jianzhen Lin, Anqiang Wang, Liangcai Wu, Yongchang Zheng, Xiaobo Yang, Xueshuai Wan, Haifeng Xu, Shuguang Chen, Haitao Zhao. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. Journal of Hematology & Oncology 2017; 10(1) doi: 10.1186/s13045-017-0511-2
|
| 46 |
Monica Mossenta, Davide Busato, Michele Dal Bo, Paolo Macor, Giuseppe Toffoli. Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. International Journal of Molecular Sciences 2022; 23(17): 10038 doi: 10.3390/ijms231710038
|
| 47 |
Byeong-Gon Na, Yun Kyu Kim, Shin Hwang, Kyung Jin Lee, Gil-Chun Park, Chul-Soo Ahn, Ki-Hun Kim, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Hunji Yang, Young-In Yoon, Eunyoung Tak, Yo-Han Park, Sung-Gyu Lee. Absence of association between pretransplant serum soluble programmed death protein-1 level and prognosis following living donor liver transplantation in patients with hepatocellular carcinoma. Medicine 2021; 100(17): e25640 doi: 10.1097/MD.0000000000025640
|
| 48 |
Xinhua Zou, Qingyu Xu, Ran You, Guowen Yin. Correlation and efficacy of TACE combined with lenvatinib plus PD‐1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features. Cancer Medicine 2023; 12(10): 11315 doi: 10.1002/cam4.5841
|
| 49 |
Mario Sznol, Lieping Chen. Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer. Clinical Cancer Research 2013; 19(5): 1021 doi: 10.1158/1078-0432.CCR-12-2063
|
| 50 |
Elias A. Said, Iman Al-Reesi, Marwa Al-Riyami, Khalid Al-Naamani, Shadia Al-Sinawi, Mohammed S. Al-Balushi, Crystal Y. Koh, Juma Z. Al-Busaidi, Mohamed A. Idris, Ali A. Al-Jabri, Jean-Pierre Vartanian. Increased CD86 but Not CD80 and PD-L1 Expression on Liver CD68+ Cells during Chronic HBV Infection. PLOS ONE 2016; 11(6): e0158265 doi: 10.1371/journal.pone.0158265
|
| 51 |
Zhi-liang Wang, Guan-zhang Li, Qiang-wei Wang, Zhao-shi Bao, Zheng Wang, Chuan-bao Zhang, Tao Jiang. PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. OncoImmunology 2019; 8(2): e1541535 doi: 10.1080/2162402X.2018.1541535
|
| 52 |
Lina Quan, Xue Chen, Aichun Liu, Yan Zhang, Xiuchen Guo, Shujie Yan, Yue Liu, Luwen Zhang. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro. PLOS ONE 2015; 10(9): e0136476 doi: 10.1371/journal.pone.0136476
|
| 53 |
Koji Sawada, Hidemi Hayashi, Shunsuke Nakajima, Takumu Hasebe, Mikihiro Fujiya, Toshikatsu Okumura. Non‐alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor. Journal of Gastroenterology and Hepatology 2020; 35(6): 1042 doi: 10.1111/jgh.14889
|
| 54 |
Chao Jiang, Xueyan Liu, Meng Wang, Guoyue Lv, Guangyi Wang. High Blood miR-802 Is Associated With Poor Prognosis in HCC Patients by Regulating DNA Damage Response 1 (REDD1)-Mediated Function of T Cells. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2019; 27(9): 1025 doi: 10.3727/096504018X15456687424096
|
| 55 |
Hao Qiu, Liang Zheng, Weifeng Tang, Pengfei Yin, Feng Cheng, Lixin Wang. Programmed death-1 (PD-1) polymorphisms in Chinese patients with esophageal cancer. Clinical Biochemistry 2014; 47(7-8): 612 doi: 10.1016/j.clinbiochem.2013.12.023
|
| 56 |
A. J. Robert McGray, Jonathan Bramson. Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. Advances in Experimental Medicine and Biology 2017; 1036: 213 doi: 10.1007/978-3-319-67577-0_14
|
| 57 |
Feng Gao, Yang Zhang, Li-Kun Wang, Yong-Li Wei, Jing-Wei Wang, Cheng-Bao Wang, Qiang Li. A Meta-Analysis of the Correlation Between the HLA-DRB1*03 Allele and Chronic Hepatitis B in the Han Chinese Population. Genetic Testing and Molecular Biomarkers 2015; 19(4): 218 doi: 10.1089/gtmb.2014.0096
|
| 58 |
Samantha M. Ruff, Timothy M. Pawlik. The role of immune checkpoint inhibitors and/or Yttrium-90 radioembolization in the management of hepatocellular carcinoma: challenges of treatment sequence. Hepatoma Research 2024; doi: 10.20517/2394-5079.2024.59
|
| 59 |
Valli De Re, Maria Lina Tornesello, Mariangela De Zorzi, Laura Caggiari, Francesca Pezzuto, Patrizia Leone, Vito Racanelli, Gianfranco Lauletta, Laura Gragnani, Angela Buonadonna, Emanuela Vaccher, Anna Linda Zignego, Agostino Steffan, Franco M. Buonaguro. Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma. Frontiers in Microbiology 2019; 10 doi: 10.3389/fmicb.2019.00475
|
| 60 |
Liang Yin, Yu Wei, Ya Liu, Xianwei Mo, Jintong Song, Weijuan Cai. Bio-responsive Au-miR-183 inhibitor enhances immunotherapy in hepatocellular carcinoma by inducing immunogenic cell death. Journal of Controlled Release 2024; 368: 498 doi: 10.1016/j.jconrel.2024.02.036
|
| 61 |
Cositha Santhakumar, Edward J. Gane, Ken Liu, Geoffrey W. McCaughan. Current perspectives on the tumor microenvironment in hepatocellular carcinoma. Hepatology International 2020; 14(6): 947 doi: 10.1007/s12072-020-10104-3
|
| 62 |
Samantha M. Ruff, Alexander H. Shannon, Joal D. Beane, Timothy M. Pawlik. Highlighting novel targets in immunotherapy for liver cancer. Expert Review of Gastroenterology & Hepatology 2022; 16(11-12): 1029 doi: 10.1080/17474124.2022.2150841
|
| 63 |
Naofumi Mukaida, Yasunari Nakamoto. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma. World Journal of Gastroenterology 2018; 24(17): 1839-1858 doi: 10.3748/wjg.v24.i17.1839
|
| 64 |
Daniel S. Chen, Bryan A. Irving, F. Stephen Hodi. Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1. Clinical Cancer Research 2012; 18(24): 6580 doi: 10.1158/1078-0432.CCR-12-1362
|
| 65 |
Fabian Finkelmeier, Özge Canli, Andrea Tal, Thomas Pleli, Jörg Trojan, Michael Schmidt, Bernd Kronenberger, Stefan Zeuzem, Albrecht Piiper, Florian R. Greten, Oliver Waidmann. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. European Journal of Cancer 2016; 59: 152 doi: 10.1016/j.ejca.2016.03.002
|
| 66 |
Carolina Boni, Valeria Barili, Greta Acerbi, Marzia Rossi, Andrea Vecchi, Diletta Laccabue, Amalia Penna, Gabriele Missale, Carlo Ferrari, Paola Fisicaro. HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications. International Journal of Molecular Sciences 2019; 20(11): 2754 doi: 10.3390/ijms20112754
|
| 67 |
Colleen S. Curran, Elad Sharon. PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma. Seminars in Oncology 2017; 44(6): 428 doi: 10.1053/j.seminoncol.2017.12.001
|
| 68 |
Maciej Gryziak, Krzysztof Wozniak, Leszek Kraj, Letycja Rog, Rafal Stec. The immune landscape of hepatocellular carcinoma‑where we are? (Review). Oncology Letters 2022; 24(5) doi: 10.3892/ol.2022.13530
|
| 69 |
Amblessed E. Onuma, Hongji Zhang, Hai Huang, Terence M. Williams, Anne Noonan, Allan Tsung. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. Gene Expression 2020; 20(1): 53 doi: 10.3727/105221620X15880179864121
|
| 70 |
Tim F. Greten, Firouzeh Korangy. Immunotherapy of Hepatocellular Carcinoma. 2017; : 121 doi: 10.1007/978-3-319-64958-0_8
|
| 71 |
Yiwen Hou, Ying Liu, Chen Chen, Zhurong Li, Zhencheng Li, Yang Liu, Huiqin Hao, Tiezheng Hou. Phenotypic profiling of CD279 and CD185 level on helper T cells in patients with autoimmune hepatitis. Scandinavian Journal of Immunology 2023; 97(1) doi: 10.1111/sji.13230
|
| 72 |
Sarah Derks, Katie S. Nason, Xiaoyun Liao, Matthew D. Stachler, Kevin X. Liu, Jie Bin Liu, Ewa Sicinska, Michael S. Goldberg, Gordon J. Freeman, Scott J. Rodig, Jon M. Davison, Adam J. Bass. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. Cancer Immunology Research 2015; 3(10): 1123 doi: 10.1158/2326-6066.CIR-15-0046
|
| 73 |
Ming-fa Chen, Yong Lin, You-chen Xia, Chan Sun, Xue-mei Feng, Meng-ji Lu, Dong-liang Yang, Jun Wu. Establishment and application of hepatitis B virus persistent replication model in IFNAR−/− mouse. Journal of Huazhong University of Science and Technology [Medical Sciences] 2013; 33(3): 392 doi: 10.1007/s11596-013-1130-y
|
| 74 |
Weimin Zhu, Rui Bao, Xiaohua Fan, Tianzhu Tao, Jiali Zhu, Jiafeng Wang, Jinbao Li, Lulong Bo, Xiaoming Deng. PD-L1 Blockade Attenuated Sepsis-Induced Liver Injury in a Mouse Cecal Ligation and Puncture Model. Mediators of Inflammation 2013; 2013: 1 doi: 10.1155/2013/361501
|
| 75 |
Michael J. Flynn, Anwar A. Sayed, Rohini Sharma, Abdul Siddique, David J. Pinato. Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. Hepatology 2019; 69(5): 2258 doi: 10.1002/hep.30337
|
| 76 |
Elisabetta Cariani, Gabriele Missale. Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications. Liver International 2019; 39(9): 1608 doi: 10.1111/liv.14192
|
| 77 |
Shin Hwang, Kyung Jin Lee, Deok-Bog Moon, Gi-Won Song, Dong-Hwan Jung, Yun Kyu Kim, Hunji Yang, Da Eun An, Sion Lee, Sung-Gyu Lee. Prognostic impact of serum soluble PD-1 and ADV score for living donor liver transplantation in patients with previously untreated hepatocellular carcinoma. Annals of Surgical Treatment and Research 2022; 102(1): 46 doi: 10.4174/astr.2022.102.1.46
|
| 78 |
Changhoon Choi, Gyu Sang Yoo, Won Kyung Cho, Hee Chul Park. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World Journal of Gastroenterology 2019; 25(20): 2416-2429 doi: 10.3748/wjg.v25.i20.2416
|
| 79 |
Fanzhi Meng, Shoumei Zhen, Bin Song. HBV‐specific CD4+ cytotoxic T cells in hepatocellular carcinoma are less cytolytic toward tumor cells and suppress CD8+ T cell‐mediated antitumor immunity. APMIS 2017; 125(8): 743 doi: 10.1111/apm.12704
|
| 80 |
Xianjing Li, Zhuo Wang, Yulian Zou, Ermei Lu, Jingjing Duan, Hongbao Yang, Qijin Wu, Xiaona Zhao, Yun Wang, Linjun You, Ling He, Tao Xi, Yong Yang. Pretreatment with lipopolysaccharide attenuates diethylnitrosamine-caused liver injury in mice via TLR4-dependent induction of Kupffer cell M2 polarization. Immunologic Research 2015; 62(2): 137 doi: 10.1007/s12026-015-8644-2
|
| 81 |
Ludovico Abenavoli, Michele Montori, Gianluca Svegliati Baroni, Maria Eva Argenziano, Francesca Giorgi, Giuseppe Guido Maria Scarlata, Francesca Ponziani, Emidio Scarpellini. Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors. Medicina 2023; 59(8): 1427 doi: 10.3390/medicina59081427
|
| 82 |
Sehar Afreen, Said Dermime. The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone. Hematology/Oncology and Stem Cell Therapy 2014; 7(1): 1 doi: 10.1016/j.hemonc.2013.09.005
|
| 83 |
Tai Hato, Lipika Goyal, Tim F. Greten, Dan G. Duda, Andrew X. Zhu. Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions. Hepatology 2014; 60(5): 1776 doi: 10.1002/hep.27246
|
| 84 |
Stephen A. Locarnini, Michael Roggendorf. Viral Hepatitis. 2013; : 96 doi: 10.1002/9781118637272.ch7
|
| 85 |
Yaron Ilan. Immune therapy for hepatocellular carcinoma. Hepatology International 2014; 8(S2): 499 doi: 10.1007/s12072-013-9501-9
|
| 86 |
Caecilia Sukowati, Loraine Kay D. Cabral, Beatrice Anfuso, Francesco Dituri, Roberto Negro, Gianluigi Giannelli, Claudio Tiribelli. PD-L1 Downregulation and DNA Methylation Inhibition for Molecular Therapy against Cancer Stem Cells in Hepatocellular Carcinoma. International Journal of Molecular Sciences 2023; 24(17): 13357 doi: 10.3390/ijms241713357
|
| 87 |
Oxana V. Makarova-Rusher, José Medina-Echeverz, Austin G. Duffy, Tim F. Greten. The yin and yang of evasion and immune activation in HCC. Journal of Hepatology 2015; 62(6): 1420 doi: 10.1016/j.jhep.2015.02.038
|
| 88 |
Zongwen Shuai, Miranda WY Leung, Xiaosong He, Weici Zhang, Guoxiang Yang, Patrick SC Leung, M Eric Gershwin. Adaptive immunity in the liver. Cellular & Molecular Immunology 2016; 13(3): 354 doi: 10.1038/cmi.2016.4
|
| 89 |
Cheon-Soo Park, Yun Kyu Kim, Eunyoung Tak, Kyung Jin Lee, Shin Hwang. Very high serum soluble PD-1 is closely associated with hepatocellular carcinoma recurrence after liver transplantation. Annals of Liver Transplantation 2022; 2(1): 21 doi: 10.52604/alt.22.0008
|
| 90 |
Junyao Yu, Shenhe Jin, Xiufeng Yin, Huaping Du. Expression of the immune checkpoint molecules PD‑L1 and PD‑1 in EBV‑associated lymphoproliferative disorders: A meta‑analysis. Experimental and Therapeutic Medicine 2023; 27(1) doi: 10.3892/etm.2023.12294
|
| 91 |
Ziwei Li, Bin Li, Dan Peng, Haiyan Xing, Guanying Wang, Pan Li, Jiming Wang, George Ye, Jianhong Chen. Expression and clinical significance of PD‑1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD‑1 monoclonal antibody. International Journal of Oncology 2018; doi: 10.3892/ijo.2018.4358
|
| 92 |
Tim F. Greten, Bruno Sangro. Targets for immunotherapy of liver cancer. Journal of Hepatology 2018; 68(1): 157 doi: 10.1016/j.jhep.2017.09.007
|
| 93 |
Antoine Hollebecque, David Malka, Charles Ferté, Michel Ducreux, Valérie Boige. Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons. European Journal of Cancer 2015; 51(3): 327 doi: 10.1016/j.ejca.2014.12.005
|
| 94 |
|
| 95 |
Christian Ihling, Bartholomew Naughton, Yue Zhang, P. Alexander Rolfe, Eveline Frick-Krieger, Luigi M. Terracciano, Isabelle Dussault. Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma. Frontiers in Medicine 2019; 6 doi: 10.3389/fmed.2019.00015
|
| 96 |
Chenxuan Li, En-di Zhang, Youzhi Ye, Zhongyun Xiao, Hanfei Huang, Zhong Zeng. Association of mitochondrial phosphoenolpyruvate carboxykinase with prognosis and immune regulation in hepatocellular carcinoma. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-64907-7
|
| 97 |
Hae Il Jung, Dongjun Jeong, Sanghee Ji, Tae Sung Ahn, Sang Ho Bae, Susie Chin, Jun Chul Chung, Hyung Chul Kim, Moon Soo Lee, Moo-Jun Baek. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. Cancer Research and Treatment 2017; 49(1): 246 doi: 10.4143/crt.2016.066
|
| 98 |
Jin Lei, Tao Yan, Linzhi Zhang, Bowen Chen, Jiamin Cheng, Xiaoqiang Gao, Zherui Liu, Yinyin Li, Shi Zuo, Yinying Lu. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors. Hepatology International 2023; 17(2): 281 doi: 10.1007/s12072-022-10450-4
|
| 99 |
Bruno Sangro, Daniel Palmer, Ignacio Melero. Immunotherapy of Hepatocellular Carcinoma. Hepatic Oncology 2014; 1(4): 433 doi: 10.2217/hep.14.16
|
| 100 |
Won‐Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Young‐Hwa Chung, Young‐Sang Lee, Sook Ryun Park, Min‐Hee Ryu, Baek‐Yeol Ryoo, So Jung Lee, Kang Mo Kim. Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma. Hepatology Communications 2020; 4(7): 1073 doi: 10.1002/hep4.1523
|
| 101 |
Valli De Re, Maria Lina Tornesello, Mariangela De Zorzi, Laura Caggiari, Francesca Pezzuto, Patrizia Leone, Vito Racanelli, Gianfranco Lauletta, Stefania Zanussi, Ombretta Repetto, Laura Gragnani, Francesca Maria Rossi, Riccardo Dolcetti, Anna Linda Zignego, Franco M. Buonaguro, Agostino Steffan. PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus‐related diseases. Liver International 2021; 41(1): 133 doi: 10.1111/liv.14667
|
| 102 |
Edward N. Harris, Justin L. Mott. Molecules, Systems and Signaling in Liver Injury. 2017; : 1 doi: 10.1007/978-3-319-58106-4_1
|
| 103 |
Samantha M. Ruff, Alexander H. Shannon, Timothy M. Pawlik. Advances in Targeted Immunotherapy for Hepatobiliary Cancers. International Journal of Molecular Sciences 2022; 23(22): 13961 doi: 10.3390/ijms232213961
|
| 104 |
Christo Kole, Nikolaos Charalampakis, Sergios Tsakatikas, Michail Vailas, Dimitrios Moris, Efthymios Gkotsis, Stylianos Kykalos, Michalis V. Karamouzis, Dimitrios Schizas. Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. Cancers 2020; 12(10): 2859 doi: 10.3390/cancers12102859
|
| 105 |
Yingxin Han, Hongmei Li, Yanfang Guan, Jian Huang. Immune repertoire: A potential biomarker and therapeutic for hepatocellular carcinoma. Cancer Letters 2016; 379(2): 206 doi: 10.1016/j.canlet.2015.06.022
|
| 106 |
Wenfeng Fang, Jianwei Zhang, Shaodong Hong, Jianhua Zhan, Nan Chen, Tao Qin, Yanna Tang, Yaxiong Zhang, Shiyang Kang, Ting Zhou, Xuan Wu, Wenhua Liang, Zhihuang Hu, Yuxiang Ma, Yuanyuan Zhao, Ying Tian, Yunpeng Yang, Cong Xue, Yue Yan, Xue Hou, Peiyu Huang, Yan Huang, Hongyun Zhao, Li Zhang. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget 2014; 5(23): 12189 doi: 10.18632/oncotarget.2608
|
| 107 |
Hao-Wen Sim, Jennifer Knox. Hepatocellular carcinoma in the era of immunotherapy. Current Problems in Cancer 2018; 42(1): 40 doi: 10.1016/j.currproblcancer.2017.10.007
|
| 108 |
Hui Li, Jun‐Quan Xia, Fang‐Shi Zhu, Zhao‐Hong Xi, Cheng‐Yu Pan, Li‐Mei Gu, Yao‐Zhou Tian. LPS promotes the expression of PD‐L1 in gastric cancer cells through NF‐κB activation. Journal of Cellular Biochemistry 2018; 119(12): 9997 doi: 10.1002/jcb.27329
|
| 109 |
Mahsa Pourhamzeh, Samieh Asadian, Hamed Mirzaei, Azita Minaei, Elahe Shahriari, Anastasia Shpichka, Hamidreza Aboulkheyr Es, Peter Timashev, Moustapha Hassan, Massoud Vosough. Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma. Molecular and Cellular Biochemistry 2023; 478(1): 23 doi: 10.1007/s11010-022-04483-4
|
| 110 |
Yu Akazawa, Toshihiro Suzuki, Toshiaki Yoshikawa, Shoichi Mizuno, Yasunari Nakamoto, Tetsuya Nakatsura. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World Journal of Meta-Analysis 2019; 7(3): 80-95 doi: 10.13105/wjma.v7.i3.80
|
| 111 |
Ryan M. Hickey, Laura M. Kulik, Halla Nimeiri, Aparna Kalyan, Sheetal Kircher, Kush Desai, Ahsun Riaz, Robert J. Lewandowski, Riad Salem. Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures. Journal of Vascular and Interventional Radiology 2017; 28(11): 1487 doi: 10.1016/j.jvir.2017.07.018
|
| 112 |
Yi Wei, Meiyi Yang, Lifeng Xu, Minghui Liu, Feng Zhang, Tianshu Xie, Xuan Cheng, Xiaomin Wang, Feng Che, Qian Li, Qing Xu, Zixing Huang, Ming Liu. Novel Computed-Tomography-Based Transformer Models for the Noninvasive Prediction of PD-1 in Pre-Operative Settings. Cancers 2023; 15(3): 658 doi: 10.3390/cancers15030658
|
| 113 |
Thomas C Wirth. Spontaneous and therapeutic immune responses in hepatocellular carcinoma: implications for current and future immunotherapies. Expert Review of Gastroenterology & Hepatology 2014; 8(1): 101 doi: 10.1586/17474124.2014.862497
|
| 114 |
Daniel L. Suzman, Lorraine Pelosof, Amy Rosenberg, Mark I. Avigan. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. Liver International 2018; 38(6): 976 doi: 10.1111/liv.13746
|
| 115 |
Rong-Miao Zhou, Yan Li, Na Wang, Xi Huang, Shi-Ru Cao, Bao-En Shan. Association of programmed death-1 polymorphisms with the risk and prognosis of esophageal squamous cell carcinoma. Cancer Genetics 2016; 209(9): 365 doi: 10.1016/j.cancergen.2016.06.006
|